60 Minutes will rebroadcast an updated report on the multinational effort to help cancer-stricken children caught in the crossfire of Russia’s invasion of Ukraine, with a specific focus on the role of St. Jude. Tune in Sunday, June 25, at 6 p.m. on CBS

Renaissance Pharma inks partnership with St. Jude Children’s Research Hospital for neuroblastoma treatment

biopharma-reporter.com/Article/2023/0… Hu14.18, a humanised antibody in development by the hospital for the treatment of newly diagnosed high-risk neuroblastoma.

NEW Publication! Promoter Modification to Reduce AAV Contamination (SJ-19-0003 (stjude.org) has a published patent application and 2022 and 23 publications listing many advantages and is available to license!

NEW Publication! Method to Activate Fetal Hemoglobin Expression (SJ-20-0020) (stjude.org) manipulates HSCs from sickle cell disease or β-thalassemia patients to induce fetal hemoglobin and is available to license! doi.org/10.1038/s41588…

We are seeking a partner to develop DNA Sequences Unique to Cancer cells and take it to market. stjude.org/research/why-s…

This genome-editing- and etiology-based strategy for cancer therapy includes an algorithm for identifying cryptic exons arising from aberrant splicing unique to cancer cells and can be applied to fusion-positive cancer patients with neo-splicing that introduced cryptic exons.

Because these neo-splice sites (or the cryptic exons) are not used in normal cells, therapies targeting these sites are expected to be nontoxic to normal cells and theoretically have an infinite therapeutic window.

The Office of Technology Licensing offers subscription communications for St. Jude innovators, technology licensing, researchers, and tech transfer news and gatherings. All this can be yours by subscribing. Subscribe | St. Jude Research (stjude.org)

December 12, 2023 is Technology Transfer Professionals Day, the 43rd anniversary of the signing of the Bayh-Dole Act, enabling Technology Transfer! (Celebrating in Memphis,TN 5pm.co.uk at Flip Side Memphis and Adrián Lamo:45pm at Crosstown Brewing, RSVP to [email protected])

11/22/22, Hemgenix, was the first gene therapy for adults living with hemophilia B to be approved by the FDA 6/29/23, Roctavian was the first gene therapy for adults with severe hemophilia A to be approved by the FDA Find out how St. Jude played a part stjude.org/research/why-s…

HAPPY #TTPD TO ALL IN #AUTM AND THOSE WHO MAKE THE INVENTIONS!